Immunitybio Inc annual ebitda for fiscal TTM was -$888 million, a decrease of 296.4% from -$224 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| EBITDA (annual) | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EBITDA | ($888M) | ($224M) | ($264M) | ($479M) | ($352M) | ($321M) | ($204M) | ($57M) | ($87M) | ($91M) | ($118M) | ($236M) | ($6M) | ($2M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| EBITDA (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| EBITDA | ($222M) | ($600M) | ($31M) | ($36M) | ($60M) | ($97M) | ($40M) | ($41M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More IBRX metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow · Shares Outstanding
All IBRX financial statements → Interactive IBRX charts →
About TickerBase · Data methodology & sources · Privacy · Terms